ArticleArthritis care & research2011
Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.
Article in Arthritis care & research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Examining the Relationship Between Rheumatoid Arthritis, Multimorbidity, and Adverse Health-Related Outcomes: A Systematic Review.Arthritis care & research · 2022Pooled it
- Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.Seminars in arthritis and rheumatism · 2014Pooled it
- Factors associated with disability in a sample of adults with arthritis.Disability and health journal · 2013Trial
- The effect of the Arthritis Self-Management Program on outcome in African Americans with rheumatoid arthritis served by a public hospital.Clinical rheumatology · 2013Trial
- Glucocorticoid sparing in rheumatoid arthritis patients treated with Janus kinase inhibitors: insights from the Japanese patient registry.Scientific reports · 2026Article
- Prevalence of Frailty and Associated Factors in a US-Wide Cohort of Rheumatic Diseases.ACR open rheumatology · 2025Article
- Predictors of serious infections in rheumatoid arthritis-a prospective Brazilian cohort.Advances in rheumatology (London, England) · 2024Observational
- Article
- Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis.Clinical rheumatology · 2022Article
- Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine.Health and quality of life outcomes · 2021Observational
- Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure.Rheumatology and therapy · 2021Article
- Functional Disability and Its Determinants in Ecuadorian Patients with Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2020Article
- A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.PharmacoEconomics · 2019Article
- Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review.Rheumatology advances in practice · 2019Article
- Motion analysis of the wrist joints in Chinese rheumatoid arthritis patients: a cross-sectional study.BMC musculoskeletal disorders · 2018Article
- Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2015Article
- Determinants of Disability in Rheumatoid Arthritis: A Community-Based Cohort Study.The open rheumatology journal · 2015Article
- Biomarkers predicting a need for intensive treatment in patients with early arthritis.Current pharmaceutical design · 2015Review
- Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2013Article
- Potential of the HAQ score as clinical indicator suggesting comprehensive multidisciplinary assessments: the Swedish TIRA cohort 8 years after diagnosis of RA.Clinical rheumatology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo examine predictors of progression of disability in rheumatoid arthritis (RA), as measured by the Health Assessment Questionnaire disability index (HAQ), and to determine rates of progression during biologic treatment.
methodsWe followed 18,485 RA patients for up to 11 years (mean 3.7 years) in a longitudinal study of RA outcomes. Patients were characterized as having moderate or severe RA versus less severe RA at study entry. Annualized progression rates were determined in multivariable analyses using generalized estimating equations.
resultsAlthough all of the demographic and severity characteristics were associated with baseline differences in HAQ score, progression was only associated with age, comorbidity, initial severity, and treatment. HAQ score increased fastest in patients ages >65 years (0.031; 95% confidence interval [95% CI] 0.028, 0.034). HAQ progression was independently associated with the presence of baseline cardiovascular disease, hypertension, diabetes mellitus, and the number of comorbid conditions. Annualized progression rates were greater in patients with mild to inactive RA (0.021; 95% CI 0.019, 0.023) than in moderate to severe RA (0.003; 95% CI 0.001, 0.006). The overall progression rate during biologic treatment was 0.008 (95% CI 0.005, 0.011); for patients with moderate to severe RA, the rate was 0.001 (95% CI -0.005, 0.003).
conclusionAge and comorbidity are important predictors of the rate of loss of functional status, and have a stronger effect on HAQ progression than does biologic treatment. There is little difference in progression rates among biologics. Patients with more severe RA progress less than those with less severe RA, a possible function of regression to the mean.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.